MAP PHARMACEUTICALS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 40 rows in 2011. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2011-12-21: Reporting owner NELSON TIMOTHY S; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2011-12-20: Reporting owner NELSON TIMOTHY S; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2011-12-12: Reporting owner GIANAKAKOS ANASTASIOS; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2011-12-12: Reporting owner GIANAKAKOS ANASTASIOS; Form 4; Security Stock Option (Right to Buy; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2011-12-21 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,638 212,549 owned after | $0.64 exercise price | 2011-12-22 | |
| 2011-12-20 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,362 219,187 owned after | $0.64 exercise price | 2011-12-22 | |
| 2011-12-12 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Bus Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,328 0 owned after | $0.74 exercise price | 2011-12-14 | |
| 2011-12-12 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Bus Officer) | 4 | Stock Option (Right to Buy Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,672 4,471 owned after | $0.74 exercise price | 2011-12-14 | |
| 2011-09-20 | CHAI CHRISTOPHER Y Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32,000 23,122 owned after | $0.74 exercise price | 2011-09-22 | |
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $3.36 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $6.39 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $13.12 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $10.37 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $16.19 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $16.15 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $15.38 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $3.36 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $6.39 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $13.12 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $10.37 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $16.19 exercise price | 2011-08-04 | ||
| 2011-08-04 holding as of filing | Borland Scott Officer (SVP, Neurology Franchise) | 3 | Stock Option (Right to Buy) Derivative · Indirect · (m) | Holding | $16.15 exercise price | 2011-08-04 | ||
| 2011-08-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 1,328 owned after | $0.74 exercise price | 2011-08-03 | |
| 2011-07-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 2,828 owned after | $0.74 exercise price | 2011-07-05 | |
| 2011-06-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 4,328 owned after | $0.74 exercise price | 2011-06-03 | |
| 2011-05-19 | Freund John Gordon Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-19 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-19 | KELLEY BERNARD J Director | 4 | Stock Option (right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-19 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-19 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-19 | MCPHERRON MATTHEW V Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $16.47 exercise price | 2011-05-23 | |
| 2011-05-09 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 13,143 owned after | $0.74 exercise price | 2011-05-10 | |
| 2011-05-02 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 5,828 owned after | $0.74 exercise price | 2011-05-03 | |
| 2011-04-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 7,328 owned after | $0.74 exercise price | 2011-04-04 | |
| 2011-03-17 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −35,846 0 owned after | $0.74 exercise price | 2011-03-21 | |
| 2011-03-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 8,828 owned after | $0.74 exercise price | 2011-03-02 | |
| 2011-02-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 10,328 owned after | $0.74 exercise price | 2011-02-03 | |
| 2011-01-26 | Friedman Charlene A Officer (VP President, Gen Counsel &Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $16.15 exercise price | 2011-01-28 | |
| 2011-01-26 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $16.15 exercise price | 2011-01-28 | |
| 2011-01-26 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $16.15 exercise price | 2011-01-28 | |
| 2011-01-26 | CHAI CHRISTOPHER Y Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $16.19 exercise price | 2011-01-28 | |
| 2011-01-26 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $16.15 exercise price | 2011-01-28 | |
| 2011-01-26 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,500 27,500 owned after | $16.15 exercise price | 2011-01-28 | |
| 2011-01-03 | GIANAKAKOS ANASTASIOS Officer (SVP, Cor & Business Dev) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 12,828 owned after | $0.74 exercise price | 2011-01-04 |